Future efforts should focus on confirming EZH2 expression in a larger cohort of MTC patients, correlating protein expression with gene expression patterns, and aiming to evaluate EZH2 expression in metastatic lesions as well. This evidence concerns the gene EZH2 and medullary thyroid gland carcinoma.